Compare NVR & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVR | ASND |
|---|---|---|
| Founded | 1980 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9B | 14.7B |
| IPO Year | 1995 | 2014 |
| Metric | NVR | ASND |
|---|---|---|
| Price | $6,460.51 | $225.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $7,157.80 | $281.50 |
| AVG Volume (30 Days) | 15.5K | ★ 621.8K |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 436.55 | N/A |
| Revenue | ★ $10,323,959,000.00 | N/A |
| Revenue This Year | N/A | $96.35 |
| Revenue Next Year | $6.60 | $44.91 |
| P/E Ratio | $14.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6,301.03 | $151.11 |
| 52 Week High | $8,618.28 | $250.74 |
| Indicator | NVR | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 43.74 |
| Support Level | $6,301.03 | $214.92 |
| Resistance Level | $7,778.36 | $236.58 |
| Average True Range (ATR) | 191.57 | 8.86 |
| MACD | -14.68 | -1.85 |
| Stochastic Oscillator | 7.44 | 27.16 |
NVR Inc is engaged in the construction and sale of residential properties, including single-family detached homes, townhomes, and condominium buildings, all of which are built on a pre-sold basis. Additionally, the company provides related services through its mortgage banking and title services businesses. Its business segments are Homebuilding and Mortgage Banking. Its geographical segments include the Mid Atlantic, the North East, the Mid East, and the South East regions of America. The majority of the company's revenue is derived from the Homebuilding Mid Atlantic segment, which includes homebuilding operations that construct and sell single-family detached homes, townhomes and condominiums in Maryland, Virginia, West Virginia, Delaware and Washington, D.C. regions.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.